title: Radioimmunoguided Surgery system improves survival for patients with recurrent colorectal cancer.
abstract: BACKGROUND
  Advanced colorectal cancer is fatal. No systemic therapies have resulted in increased patient survival.
  
  
  METHODS
  One hundred thirty-one patients with recurrent colorectal cancer enrolled in two prospective nonrandomized studies using Radioimmunoguided Surgery (RIGS) system from May 1986 to April 1992 have been analyzed. Eighty-six patients were injected with the anti-tumor-associated glycoprotein (TAG) antibody B72.3, and 45 patients were injected with the second-generation anti-TAG monoclonal antibody CC49. Both monoclonal antibodies were radiolabeled with iodine 125. Both traditional and RIGS explorations were used to determine resectability. Follow-up was a minimum of 28 months.
  
  
  RESULTS
  Forty-nine (37.4%) of the 131 patients underwent a curative resection. Twenty-seven of the patients (55%) are alive 2 to 8 years after operation. The cancers of the remaining 82 patients were unresectable, and only two patients (2%) are alive. In this unresectable group alternative intraoperative therapeutic methods (intraoperative radiation therapy, intraperitoneal hyperthermic perfusion, hepatic lines, and brachytherapy) were tried in 11 patients with two survivors. There were no survivors in 18 patients whose cancers were found to be traditionally resectable but unresectable with RIGS or in the 53 patients whose cancers were clearly unresectable by traditional exploration. Patients selected for curative resection had significantly increased survival (p < 0.0001).
  
  
  CONCLUSIONS
  As an intraoperative tool RIGS significantly improves the selection of patients for curative resection.
authors.affiliation: Department of Surgery, Ohio State University Hospitals, Columbus 43210, USA.
authors.forename: D J
authors.initials: DJ
authors.lastname: Bertsch
authors.forename: W E
authors.initials: WE
authors.lastname: Burak
authors.forename: D C
authors.initials: DC
authors.lastname: Young
authors.forename: M W
authors.initials: MW
authors.lastname: Arnold
authors.forename: E W
authors.initials: EW
authors.lastname: Martin
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000601:surgery*; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D015179:Colorectal Neoplasms / Q000401:mortality / Q000601:surgery*; D006023:Glycoproteins / Q000032:analysis*; D006801:Humans; D007430:Intraoperative Care; D007457:Iodine Radioisotopes; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000601:surgery*; D011446:Prospective Studies; D016719:Radioimmunodetection / Q000295:instrumentation*; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D006023:Glycoproteins; D007457:Iodine Radioisotopes; C047052:tumor-associated antigen 72